Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher McCabe

Showing results (131-140 of 150) with videos related to

Pageof 15
Sort By:
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
Health Technology Assessment (Winchester, England)|September 28, 2019
Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCTJane Nixon, Sarah Brown, Isabelle L Smith, et al.
BMC Musculoskeletal Disorders|December 26, 2014
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drugNuria C Navarro Coy, Sarah Brown, Ailsa Bosworth, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
Health Economics, Policy, and Law|September 27, 2023
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessmentVictoria Charlton, Michael DiStefano, Polly Mitchell, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
International Journal of Technology Assessment in Health Care|June 2, 2025
Defining early health technology assessment: building consensus using Delphi techniqueJanneke P C Grutters, Janet Bouttell, Payam Abrishami, et al.
Health Technology Assessment (Winchester, England)|September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCTHelena Earl, Louise Hiller, Anne-Laure Vallier, et al.
Plos Biology|November 14, 2013
Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debateTimothy Caulfield, Jim Evans, Amy McGuire, et al.
The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Pageof 15

Showing results (131-140 of 150) with videos related to

Sort By:
Pageof 15
Health Technology Assessment (Winchester, England)|February 12, 2016
OPTIMA prelim: a randomised feasibility study of personalised care in the treatment of women with early breast cancerRobert C Stein, Janet A Dunn, John M S Bartlett, et al.
Health Technology Assessment (Winchester, England)|September 28, 2019
Comparing alternating pressure mattresses and high-specification foam mattresses to prevent pressure ulcers in high-risk patients: the PRESSURE 2 RCTJane Nixon, Sarah Brown, Isabelle L Smith, et al.
BMC Musculoskeletal Disorders|December 26, 2014
The 'Switch' study protocol: a randomised-controlled trial of switching to an alternative tumour-necrosis factor (TNF)-inhibitor drug or abatacept or rituximab in patients with rheumatoid arthritis who have failed an initial TNF-inhibitor drugNuria C Navarro Coy, Sarah Brown, Ailsa Bosworth, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|December 16, 2017
Value of Information Analysis of Multiparameter Tests for Chemotherapy in Early Breast Cancer: The OPTIMA Prelim TrialPeter S Hall, Alison Smith, Claire Hulme, et al.
Health Economics, Policy, and Law|September 27, 2023
We need to talk about values: a proposed framework for the articulation of normative reasoning in health technology assessmentVictoria Charlton, Michael DiStefano, Polly Mitchell, et al.
Journal of the National Cancer Institute|May 1, 2016
Comparing Breast Cancer Multiparameter Tests in the OPTIMA Prelim Trial: No Test Is More Equal Than the OthersJohn M S Bartlett, Jane Bayani, Andrea Marshall, et al.
International Journal of Technology Assessment in Health Care|June 2, 2025
Defining early health technology assessment: building consensus using Delphi techniqueJanneke P C Grutters, Janet Bouttell, Payam Abrishami, et al.
Health Technology Assessment (Winchester, England)|September 4, 2020
Six versus 12 months' adjuvant trastuzumab in patients with HER2-positive early breast cancer: the PERSEPHONE non-inferiority RCTHelena Earl, Louise Hiller, Anne-Laure Vallier, et al.
Plos Biology|November 14, 2013
Reflections on the cost of "low-cost" whole genome sequencing: framing the health policy debateTimothy Caulfield, Jim Evans, Amy McGuire, et al.
The Lancet. Oncology|February 16, 2023
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trialJanet E Brown, Kara-Louise Royle, Walter Gregory, et al.
Pageof 15